NEWS

WIRES

OTHER

Bioterrorism Expert, Dr. Edward L. Stephen, Appointed to Lead MDM Group Biodefense Division

MDM Group, Inc. advises that the Company has appointed Dr. Edward L. Stephen, DVM, (LTC, US Army Reserves assigned to USAMRIID, Ft. Detrick) to head up the Company's bioterrorism and biological warfare defense division.

Dr. Stephen's direct experience in biodefense stems from over a decade with the US Army Special Operations Division and US Army Medical Research Institute of Infectious Diseases (USAMRIID) at Fort Detrick, MD, where he played key roles in bioterrorism defense including vulnerability assessments of targets such as the New York subway system, Pentagon, and elements of the food chain such as feedlots and stock yards. Dr. Stephen held leadership positions in drug discovery and development programs pertaining to agents of biological warfare and terrorism potential, including work conducted with Class A agents, those considered highest priority, as well as agents in Categories B and C.

For the past five years, Dr. Stephen has been a Senior Project Manager at the International Science and Technology Center (ISTC), a 37-nation consortium creating peacetime opportunities that take advantage of the scientific experience and expertise of personnel formerly involved in the R&D of biological weapons of mass destruction (BioWMD) in Russia. As a facet of establishing collaborative research projects with the ISTC, Dr. Stephen was responsible for creating collaborative research projects with U.S. agencies, companies of all sizes, and universities. A predominant focus in this work was biodefense research and development including an important joint discovery project to find new drugs for the prevention and treatment of smallpox.

Dr. Stephen has also managed several civilian pharmaceutical development projects, including Battelle's Prime Contract to perform GLP toxicology studies in support of the National Cancer Institute (NCI). He is the author of over fifty publications in technical, peer-reviewed journals and has presented at numerous national and international scientific meetings. Dr. Stephen has been a member of several veterinary societies and associations, in addition to New York Academy of Sciences, Regulatory Affairs Professional Society, American Chemical Society, and International Union of Pure and Applied Chemistry.

In his role with MDM, Dr. Stephen's initial task will be to establish the inaugural direction of MDM's biodefense division and to select and initiate its first collaborative projects.

MDM Group is a development stage advanced technologies research and development Company focused on security and Homeland Defense industries with interests that include the ShockRounds(TM) technology which is positioned as a major breakthrough in the munitions, military and law enforcement industries. This patent pending development introduces an "electric" charge to traditional ammunition and other projectiles such as rubber bullets through the combination of existing ballistic and piezoelectric technologies. See: www.shockrounds.com

Safe Harbor Statement

The information in this release, other than historical information, may be considered forward-looking statements within the provisions of the Private Securities Litigation Reform Act of 1995. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.

For further information see: www.shockrounds.com and www.mdmgroupinc.com

MDM Group is featured on www.Homelanddefensestocks.com, a global investment research portal for defense and security.